Apyx Medical Corporation (APYX) Financial Statements (2024 and earlier)

Company Profile

Business Address 5115 ULMERTON ROAD
CLEARWATER, FL 33760
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18,47916,25510,19214,83320,06326,234
Cash and cash equivalents18,47916,25510,19214,83320,06326,234
Receivables20,13918,13518,24616,65818,01520,117
Inventory, net of allowances, customer advances and progress billings11,16710,94611,79712,0429,6777,019
Inventory11,16710,94611,79712,0429,6777,019
Contract with customer, asset, after allowance for credit loss   100   
Asset, held-for-sale, not part of disposal group  4,569    
Other undisclosed current assets3,1002,7792,6372,7742,7701,441
Total current assets:52,88552,68442,97246,30750,52554,811
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization97106115124176127
Operating lease, right-of-use asset5,42164671077465990
Property, plant and equipment2,1182,1096,7616,8106,8426,655
Other noncurrent assets1,9081,2391,2171,2531,2691,314
Total noncurrent assets:9,5444,1008,8038,9618,9468,186
TOTAL ASSETS:62,42956,78451,77555,26859,47162,997
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,6257,41011,5977,7419,0926,295
Taxes payable135143163
Employee-related liabilities8791,4231,426
Accounts payable2,6581,9052,6692,0702,5872,562
Accrued liabilities5,9675,5058,9284,6574,9392,144
Deferred revenue  1,053   759
Debt8,9208,811374285116
Other undisclosed current liabilities1,4841,2522163,4112,1754,434
Total current liabilities:19,02918,52611,85011,19411,35211,604
Noncurrent Liabilities
Long-term debt and lease obligation63687353260713
Long-term debt, excluding current maturities      
Finance lease, liability636873789313
Liabilities, other than long-term debt6,6041,9762,0591,3251,3491,537
Deferred revenue1,3261,3431,4081,1921,2071,386
Other liabilities185185181133142151
Operating lease, liability5,093448470454514 
Total noncurrent liabilities:6,6672,0442,1321,8571,9561,550
Total liabilities:25,69620,57013,98213,05113,30813,154
Equity
Equity, attributable to parent36,59636,05237,58241,99045,90549,561
Common stock353535353434
Additional paid in capital76,77375,23573,28271,64169,79368,023
Accumulated deficit(40,212)(39,218)(35,735)(29,686)(23,922)(18,496)
Equity, attributable to noncontrolling interest137162211227258282
Total equity:36,73336,21437,79342,21746,16349,843
TOTAL LIABILITIES AND EQUITY:62,42956,78451,77555,26859,47162,997

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues13,56912,14212,6119,11410,29212,493
Cost of revenue
(Cost of Goods and Services Sold)
(4,290)(4,569)(4,370)(3,357)(3,378)(4,274)
Gross profit:9,2797,5738,2415,7576,9148,219
Operating expenses(13,206)(13,184)(14,174)(11,539)(12,890)(14,090)
Other operating income (expense), net  (5)(551)(35)607(21)
Other undisclosed operating income (loss) 2,692555135(607)21
Operating loss:(1,235)(5,611)(5,933)(5,782)(5,976)(5,871)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
282(188)1937622(27)
Interest and debt expense(543)(234)(3)(1)(3)(8)
Loss from continuing operations before equity method investments, income taxes:(1,496)(6,033)(5,917)(5,746)(5,357)(5,906)
Other undisclosed income from continuing operations before income taxes5432343138
Loss from continuing operations before income taxes:(953)(5,799)(5,914)(5,745)(5,354)(5,898)
Income tax expense (benefit)(66)2,267(151)(50)(96)(70)
Loss from continuing operations:(1,019)(3,532)(6,065)(5,795)(5,450)(5,968)
Loss before gain (loss) on sale of properties:(5,795)(5,450)(5,968)
Net loss:(1,019)(3,532)(6,065)(5,795)(5,450)(5,968)
Net income attributable to noncontrolling interest254916312423
Net loss available to common stockholders, diluted:(994)(3,483)(6,049)(5,764)(5,426)(5,945)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(1,019)(3,532)(6,065)(5,795)(5,450)(5,968)
Comprehensive loss:(1,019)(3,532)(6,065)(5,795)(5,450)(5,968)
Comprehensive income, net of tax, attributable to noncontrolling interest254916312423
Comprehensive loss, net of tax, attributable to parent:(994)(3,483)(6,049)(5,764)(5,426)(5,945)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: